VILDAPRIME M 50/500MG TAB

Distributor inventory | Tablet

Type 2 diabetes mellitus (to improve glycaemic control) when diet and exercise are insufficient; used when metformin alone is not enough or as combination therapy as advised by a doctor.

Vildagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1, GIP), leading to increased insulin release and reduced glucagon in a glucose-dependent manner. Metformin decreases glucose production by the liver and improves insulin sensitivity, helping the body use glucose better.

Take orally as prescribed by the physician, usually with meals to reduce stomach upset. Swallow whole with water; do not crush/chew unless advised. Dose and duration depend on blood sugar control, kidney function and tolerability.

Nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, metallic taste, headache, dizziness, upper respiratory tract infection, hypoglycaemia (especially with other antidiabetics), fatigue

Prescription-only antidiabetic. Metformin may rarely cause lactic acidosis—risk increases with kidney impairment, severe infection, dehydration, alcohol excess, liver disease or heart failure; seek urgent care for fast breathing, severe weakness, abdominal pain. Monitor renal function before and during therapy; avoid/adjust in reduced eGFR as per clinician. Vildagliptin can rarely affect liver enzymes or cause pancreatitis—report persistent severe abdominal pain; periodic LFT monitoring may be advised. Hold metformin temporarily before/after iodinated contrast procedures and during major surgery as advised. Use caution in elderly and those prone to hypoglycaemia when combined with insulin/sulfonylureas.